Elicera Therapeutics AB (ELIC) - Total Assets
Based on the latest financial reports, Elicera Therapeutics AB (ELIC) holds total assets worth Skr37.30 Million SEK (≈ $4.01 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Elicera Therapeutics AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Elicera Therapeutics AB - Total Assets Trend (2014–2024)
This chart illustrates how Elicera Therapeutics AB's total assets have evolved over time, based on quarterly financial data. Check Elicera Therapeutics AB earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Elicera Therapeutics AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Elicera Therapeutics AB's total assets of Skr37.30 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 95.8% |
| Accounts Receivable | Skr881.87K | 3.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Elicera Therapeutics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ELIC market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elicera Therapeutics AB's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 95.8% of total assets in 2024, up from 5.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Elicera Therapeutics AB Competitors by Total Assets
Key competitors of Elicera Therapeutics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Elicera Therapeutics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.35 | 4.02 | 5.12 |
| Quick Ratio | 5.35 | 4.02 | 5.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr30.33 Million | Skr23.37 Million | Skr9.71 Million |
Elicera Therapeutics AB - Advanced Valuation Insights
This section examines the relationship between Elicera Therapeutics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.16 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | Skr27.56 Million |
| Market Capitalization | $14.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elicera Therapeutics AB's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Elicera Therapeutics AB's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Elicera Therapeutics AB (2014–2024)
The table below shows the annual total assets of Elicera Therapeutics AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr27.56 Million ≈ $2.97 Million |
-8.67% |
| 2023-12-31 | Skr30.18 Million ≈ $3.25 Million |
-34.83% |
| 2022-12-31 | Skr46.31 Million ≈ $4.98 Million |
-15.40% |
| 2021-12-31 | Skr54.74 Million ≈ $5.89 Million |
+334.78% |
| 2020-12-31 | Skr12.59 Million ≈ $1.35 Million |
+1936.85% |
| 2019-12-31 | Skr618.10K ≈ $66.52K |
-23.61% |
| 2018-12-31 | Skr809.16K ≈ $87.08K |
-0.43% |
| 2017-12-31 | Skr812.69K ≈ $87.46K |
-13.38% |
| 2016-12-31 | Skr938.25K ≈ $100.97K |
-20.84% |
| 2015-12-31 | Skr1.19 Million ≈ $127.55K |
+20.02% |
| 2014-12-31 | Skr987.50K ≈ $106.27K |
-- |
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more